Andrew Wayland

Chief Research Officer

Andrew is a Life Science professional and strategist with over 16 years of experience building disruptive partnerships across academia, CROs, diagnostics, biotechnology, pharmaceutical and medical device organizations.

His professional goal is to successfully impact healthcare organizations to advance innovative therapeutic discoveries for the treatment of human disease via maximizing efficiencies and accelerate cost-effective drug, medical device and therapeutic development and approval efforts.

Andrew is highly recognized for accomplishments with Business Development and Sponsored Research Funding, Clinical Research Operations, and Strategic Collaborations. 

Sponsored research funding derived from Federal (NIH, DoD, NSF), State (CPRIT), Foundation/Philanthropic, and Biopharma/Pharmaceutical research funding proposals (RFPs)

Therapeutic Specialty Areas: Oncology (Hematology and Solid Tumor), Immunology, Neurology/CNS, Clinical Pharmacology, Digital Health (AI), Medical Device, Therapeutic Diagnostics, Healthcare Prevention, Educational Services and Other Indications

Andrew attended the University of Texas-Austin and obtained his B.A. in Economics prior to entering the clinical research and healthcare environment. During his tenure at the private research site specializing in CNS/Neurology, he obtained his Masters in Business Administration from University of Houston-Clear Lake.